Compare AbbVie Inc (ABBV) vs AMETEK, Inc. (AME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs AMETEK, Inc. — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while AMETEK, Inc. trades at $255.78 (market cap $57.98B). The key difference: AbbVie Inc is far larger — about 7.6× AMETEK, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | AME | |
|---|---|---|
Market Cap | $438.19B | $57.98B |
Sector | Health | Industrials |
52-Week High | $263.58 | $256.30 |
52-Week Low | $197.38 | $179.28 |
Enterprise Value | $502.45B | $59.52B |
Dividend Yield | 2.79% | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
AME trades at $253.66, up 0.91% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $2.09 vs. $1.99 expected), revenue growth to $7.40B in 2025, and robust profitability (20.04% net margin). Recent news highlights momentum in 3D printing and electronics testing sectors. Analyst consensus is strongly bullish with a $281.86 price target.
Outlook remains positive given earnings momentum and raised guidance, but risks include elevated valuation (P/E 37.08) and RSI overbought signals. Institutional support is strong with no sell ratings. The stock offers growth potential but requires monitoring of valuation metrics amid current levels near resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
